Navigation Links
Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
Date:2/23/2009

y resolution of fever. Viral shedding (time weighted change from baseline in viral titer) was reduced by a median of -2.0 logs for peramivir 200 mg, -2.1 logs for peramivir 400 mg, and -1.9 logs for oseltamivir (p=0.908). There was no mortality in the primary efficacy population, and there were no clinical relapses. Patients were discharged from hospital after a median of 4.0 days for peramivir 200 mg, 3.8 days for peramivir 400 mg, and 4.0 days for oseltamivir (p=0.994). The median number of days required for resumption of usual activities was 8.8 days for peramivir 200 mg, 9.0 days for peramivir 400 mg, and 13.7 days for oseltamivir (p=0.276).

"We are encouraged by these data and are currently working with the U.S. Food and Drug Administration to determine the next steps for peramivir as a treatment for patients hospitalized with influenza," said Dr. William P. Sheridan, BioCryst's Chief Medical Officer. "There are currently no approved treatment options for the 200,000 patients hospitalized for influenza each year and we believe peramivir may be a potential new option for these patients."

"This study greatly enhances our knowledge of the clinical and virologic course of influenza in hospitalized patients who receive neuraminidase inhibitors," stated Dr. Ison. "Peramivir holds promise as a once-daily intravenous treatment that is safe and potentially effective for use in patients with acute influenza, including the elderly and patients with underlying cardiac or pulmonary disease."

The multicenter, randomized, double-blind, double-dummy, active-controlled, Phase 2 study enrolled 137 patients, who tested positive by rapid antigen test (RAT) for influenza and had one or more criteria for hospitalization, namely: age greater than or equal to 60 years, chronic lung disease, congestive heart failure, diabetes mellitus, low oxygen saturation, low blood pressure, or severity of illness requiring supportive care. O
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
4. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
5. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
6. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
7. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
8. Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
9. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... -- The U.S. Department of Health and Human Services (HHS) ... Case Medical Center Seidman Cancer Center totaling $4.7 million ... care for patients with complex cancer. ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... Virtual Radiologic (vRad), a technology-enabled national radiology practice, ... solution, has been selected by Abbeville Area Medical ... South Carolina. AAMC selected vRad,s ... on-premise PACS that was developed by radiologists for ...
... NEW YORK, Nov. 29, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0693503/Medical-Devices---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics This ... from the following Asian countries: Azerbaijan, China, ...
Cached Medicine Technology:vRad Selected by Abbeville Area Medical Center for PACS Replacement 2vRad Selected by Abbeville Area Medical Center for PACS Replacement 3Medical Devices - Asia 2
(Date:7/12/2014)... According to the new market research ... Systems, and Naval Systems) - Global Forecasts and Analysis ... Surveillance Radar market are estimated to be $6.08 billion ... of 5.97% to reach $8.61 billion by 2020. , ... figures spread through 161 pages and in-depth TOC on ...
(Date:7/12/2014)... Passenger Information System market is estimated to grow from ... at an expected CAGR of 26.5% for the period ... in North America is well developed and network infrastructure ... the region. The growing ridership figures in public transport ... driving the North American Passenger Information System market at ...
(Date:7/12/2014)... Dennis Thompson HealthDay Reporter ... to guarantee that a surgical technique used to grind up ... the risk of spreading cancer to other parts of a ... panel to the Food and Drug Administration also said that ... morcellation -- should sign a written consent stating that they ...
(Date:7/12/2014)... The Security Analytics market is estimated to ... by 2019, at an expected CAGR of 9.7% for ... counter the increasing number of security breaches, continued line ... systems in organizations are enormous. Vendors in the security ... architecture to develop better and more secure systems. , ...
(Date:7/12/2014)... -- If you make exercise fun, you,ll eat less after ... adults were led on a 1.4-mile walk and were either ... walk. The participants were given lunch after the walk, and ... 35 percent more chocolate pudding for dessert than those who ... experiment, 46 adults were given mid-afternoon snacks after their walk. ...
Breaking Medicine News(10 mins):Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Make Exercise Fun, Eat Less Afterwards 2
... 31, 2010 The first study of Ewing,s sarcoma that ... growth has identified two potential anti-cancer drug targets, according to ... published this month in the journal Molecular Cancer . ... occur most frequently in the bones of teenagers. They represent ...
... dying in road accidents on the basis of the time ... clear reducing the time between an accident taking place ... 15 minutes would cut the risk of death by one-third. ... medical services arrive is 25 minutes in Spain", Roco Snchez-Mangas, ...
... Faith based schools are on the rise in the ... at odds with legislation on equality? Research that appears ... published by SAGE shows what happens when school values ... for gay students and staff. The UK Government, ...
... cancer recurrence after surgical resection. However, it is difficult ... of anticancer drugs, if at all. Building on existing ... the Journal of Thoracic Oncology (JTO), analyzed ... cancer (NSCLC) based on the histoculture drug response assay ...
... IL Young adults who get fewer than eight hours ... a combination of high levels of depressive and anxious symptoms, ... the journal SLEEP . Using an average self-reported ... reference, the study found a linear association between sleep durations ...
... Lisbon, Portugal: Hundreds of millions of euros are ... patients consulting community pharmacists rather than going straight to ... (Wednesday 1 September) at the annual conference of the ... 500 million was freed up in one year for ...
Cached Medicine News:Health News:TGen finds therapeutic targets for rare cancer in children 2Health News:10 minutes could prevent one-third of road deaths 2Health News:Keeping faith -- schools must balance ethos with equality 2Health News:Lung cancer survival rates improved through use of individualized chemotherapy 2Health News:Study links shorter sleep durations with greater risks of mental distress in young adults 2Health News:Study links shorter sleep durations with greater risks of mental distress in young adults 3Health News:Health advice from pharmacists saves hundreds of millions of euros 2Health News:Health advice from pharmacists saves hundreds of millions of euros 3
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
... offers state-of-the-art quality in an instrument of ... durability. Low profile cutting tips allow access ... I instruments are available in just about ... required for large and small joint arthroscopic ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... The Series I Instrument program offers ... low profile, while maintaining strength and durability. ... pathology in tight joint spaces. Series I ... cutting tip style, size and angle required ...
Medicine Products: